LINCOLN vs NECLIFE: Stock Comparison
LINCOLN PHARMA is the larger company by market capitalisation. LINCOLN PHARMA shows a higher ROE, a higher dividend yield and faster revenue growth, while NECTAR LIFESCIENCES shows a lower P/E and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
LINCOLN leads 7; NECLIFE leads 3 of 12
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | LINCOLN | NECLIFE |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | LINCOLN | NECLIFE |
|---|---|---|
| Live Price | ₹510.85 | ₹10.76 |
| Day Change | -0.72% | -4.69% |
| Volume | 61,149 | 2.35 L |
| 52-Week High | ₹770 | ₹21.4 |
| 52-Week Low | ₹440 | ₹9.3 |
| Distance from 52W High | -33.66% | -49.72% |
Valuation
| Metric | LINCOLN | NECLIFE |
|---|---|---|
| Market Cap | ₹1,023 Cr | ₹209 Cr |
| P/E Ratio | 10.61x | 0x |
| P/B Ratio | 1.35x | 0.4x |
| EPS | ₹18.09 | ₹-0.79 |
| Book Value | ₹378.25 | ₹29.97 |
| Dividend Yield | 0.35% | 0% |
Growth
| Metric | LINCOLN | NECLIFE |
|---|---|---|
| Revenue Growth (TTM YoY) | 11.4% | -3.41% |
| EPS Growth (TTM YoY) | 0.6% | 0% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | LINCOLN | NECLIFE |
|---|---|---|
| ROE | 11.6% | -9.85% |
| ROCE | 10.97% | -8.89% |
| Net Margin | 13.1% | -11.28% |
| Operating Margin | 17.38% | — |
| Debt to Equity | 0.01x | 0x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | LINCOLN | NECLIFE |
|---|---|---|
| Promoter Holding | 49.78% | 51.84% |
| FII Holding | 4.6%▼ 0.59 pp | 0.5% |
| DII Holding | 0.27%▼ 0.82 pp | 3.9%▲ 0.16 pp |
| Public Holding | 45.36%▲ 1.42 pp | 43.74%▼ 0.15 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: LINCOLN PHARMA and NECTAR LIFESCIENCES.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.